Medtronic CoreValve System Receives FDA Approval for Patients at High Risk for Surgery

Accelerated Approval Obtained after Clinical Outcomes with Self-Expanding Valve Prove Superior to Surgical Aortic Valve Replacement at One Year

CoreValve System Now Available to More U.S. Patients than any Other Transcatheter Aortic Valve

MINNEAPOLIS – June 12, 2014 – Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval of the self-expanding transcatheter CoreValve® System for patients with severe aortic stenosis who are at high risk for surgery. This approval is based on groundbreaking research that showed clinical outcomes at one year with the CoreValve System were superior to open-heart surgery, the current gold standard for aortic valve replacement.

The FDA approved the CoreValve System without the need for an independent device advisory panel review due to its exceptionally positive clinical results demonstrated in the High Risk Study of the CoreValve U.S. Pivotal Trial. The head-to-head study, comparing transcatheter aortic valve replacement (TAVR) with the CoreValve System to traditional surgical aortic valve replacement, met its primary endpoint with high survival at one year for patients receiving the CoreValve System (85.8 percent), which was statistically superior to patients receiving a surgical valve (80.9 percent).

“This rigorous trial has defined a new standard for transcatheter valve performance, with superiority results that give physicians even more confidence in making TAVR treatment decisions,” said David H. Adams, MD, chair of the Department of Cardiothoracic Surgery at the Mount Sinai Hospital, New York City, national co-principal investigator of the CoreValve U. S. Pivotal Trial. “With this approval, we can treat more patients due to the broad range of CoreValve sizes, and we have an option compared to surgery that provides a greater chance for a longer life while minimizing the risk of stroke.”

For patients treated with the CoreValve System in the High Risk Study, rates of stroke were low and not statistically different than rates experienced by surgery patients. The rate of MACCE (major adverse cardiovascular or cerebral events) was significantly better for CoreValve patients at one year, and overall hemodynamic performance was better in CoreValve patients than in surgical patients across all time points.

The CoreValve System was designed to serve the clinical needs of the broadest range of patients with aortic stenosis. The valve’s self-expanding frame provides controlled deployment, enabling physicians to accurately place the valve inside a patient’s original valve, while conforming to the native annulus to provide a seal. The FDA approved the entire CoreValve platform – including the 23mm, 26mm, 29mm and 31mm size valves – all of which are delivered through the smallest commercially available TAVR delivery system (18Fr, or approximately ¼ inch), making it possible to treat patients with difficult or small vasculature.

The CoreValve System was approved by the FDA for patients at extreme risk in January 2014. Since receiving CE (Conformité Européenne) Mark in 2007, the CoreValve System has been implanted in more than 60,000 patients in more than 60 countries.

For more information about the CoreValve System, call 877-526-7890 or go to